|Day Low/High||16.21 / 17.18|
|52 Wk Low/High||6.96 / 25.00|
The indices may need a rest, but stock-pickers have an edge.
Pharma giant aims to develop cancer drug delivery technology. Halozyme shares are up more than 16% in pre-market trading.
Bristol-Myers Squibb Company (NYSE:BMY) and Halozyme Therapeutics, Inc.
Company also announces agreement with online marketing giant to drive Chinese sales
First Study Evaluating Combination of PEGPH20 and atezolizumab in Pancreatic Cancer
--Findings in Two Oral Presentations and Three Poster Presentations Continue to Support Ongoing HALO-301 Phase 3 Study--
The most recent short interest data has been released for the 05/31/2017 settlement date, which shows a 3,135,029 share decrease in total short interest for Halozyme Therapeutics Inc , to 21,693,822, a decrease of 12.63% since 05/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
-Presentation Includes Newly Reported Objective Response Rate and Patient Baseline Characteristics from HALO-202-
Lion Biotechnologies, XBiotech and Halozyme Therapeutics were among the biotech movers in premarket trading on Friday.
-HALO-202 Study Met Primary, Key Secondary Endpoints and Demonstrated a Statistically Significant Improvement in Progression-Free Survival (PFS) in Patients with High Levels of Hyaluronan-
Here's how to potentially rake in some fat profits off a number of hot breakout setups.
Halozyme Therapeutics, Omeros and Aralez Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.
The market response to the Fed was quite extreme, although there really wasn't any major development.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.